The ubiquitylation/deubiquitylation balance in cells is maintained by 34
INTRODUCTION 59
Ubiquitin signaling is now recognized as a fundamental molecular mechanism 60 tightly regulating a broad range of intracellular events 1-3 . Ubiquitylation is a 61 highly dynamic biochemical modification in which an ubiquitin (Ub) moiety is 62 attached to a protein. This process is catalyzed by the sequential actions of 63
Ub-activating enzyme (E1), Ub-conjugating enzymes (E2) and Ub-protein 64 ligases (E3) that bind Ub to different lysine (K) residues in the substrate, 65 resulting in mono or poly Ub chains (Reviewed in 4 ). Ubiquitylated substrates 66 are then recognized by proteins containing ubiquitin binding domains and 67 directed to different fates. For example, K48 usually targets proteins for 68 proteasomal degradation 4 , while K63-linked polyUb regulates protein 69 activation, subcellular localization or degradation in the lysosome (autophagy) 70
and is known to be relevant for DNA repair (Reviewed in 5 ). Ubiquitylation and 71 proteolysis by the Ubiquitin-proteasome pathway (UPP) are now well-known 72 as important mechanisms in the nervous system as this proteolytic pathway is 73 known to degrade misfolded or short-lived regulatory proteins (Reviewed in 74
With the goal of identifying substrates of the DUB activity in neuronal cells, we 114 searched for changes in the ubiquitome of neuronally differentiated SH-SY5Y 115 cells lacking ATXN3 (ATXN3 shRNA cells - Figure EV1A -B) 25 , taking advantage 116 of a recently developed methodology that combines capture of the whole 117 spectrum of polyubiquitylated proteins in a cell extract using an enrichment by 118
Tandem Binding Ubiquitin Entities (TUBEs) followed by mass spectrometry 119 analysis (TUBEs-LC-MS/MS) 30 . Figure 1A summarizes the steps followed for 120 the purification and identification of the polyubiquitylated proteins in 121 ATXN3 shRNA and scrambled control shRNA (SCR shRNA ) cells. The integration 122 of the data and the comparison between the proteins identified in ATXN3 shRNA 123 versus SCR shRNA cells resulted in a list of proteins with altered 124 polyubiquitylation in cells lacking ATXN3; among these are potential targets of 125 the DUB activity of ATXN3, i.e., putative ATXN3 substrates. In each pulldown 126 experiment, around 1200-1300 proteins were identified. When the results of 127 all the independent experiments were merged, we observed that many of 128 these proteins were only sporadically detected across the different 129 experiments; for the remaining analysis, these proteins were excluded, 130 reducing the list to 615 consistently identified proteins. From these, 193 131 proteins showed altered levels in the polyubiquitylated fraction in ATXN3 shRNA 132 cells when compared to the SCR shRNA controls (p<0.05) (Table EV1 ). The 133 majority of these polyubiquitylated proteins were either not detected (44.04%) 134 or showed decreased levels (24.35%) in ATXN3 shRNA cells when compared to 135 the controls. These proteins can be grouped into 10 functional networks, the 136 most representative being related to: (i) Gene expression, DNA replication, 137 recombination and repair (17.7%), (ii) RNA post-transcriptional modification 138 (13.3%), (iii) Molecular transport, RNA trafficking (10.8%), (iv) Cell death and 139 survival (8.9%) and (v) Organ morphology (8.9%) ( Figure 1B) . The fact that a 140 significant proportion of the proteins with altered polyubiquitylation in 141 ATXN3 shRNA cells are RNA metabolism-related proteins, around 8% of them 142 being splicing factors (Table 1) , suggested to us that ATXN3 could be playing 143 a role in mRNA splicing, a previously undescribed role for this DUB. 144 145
Cells lacking ATXN3 show global perturbation of splicing 146
We hypothesized that absence of ATXN3 could lead to a deregulation of the 147 pre-mRNA splicing process. To address this, we used three hybrid minigene 148 reporter plasmids: the pyPY minigene, representing splicing events with 149 alternative competing 3' acceptor sites/splice sites, the AdML minigene, 150
representing constitutive/strong splicing events, and the α-globin minigene, for 151 which the alternative splicing (exon skipping) is indicative of the performance 152 of regulatory splicing factors such as hnRNP and SF proteins 31, 32 . As shown 153 in Figure 2A -D, knockdown of ATXN3 significantly altered the processing of 154 the three splicing reporters, suggesting a general deregulation of splicing in 155 the absence of this protein. Interestingly, overexpression of a catalytically inert 156 version of ATXN3 in SH-SY5Y cells (ATXN3_C14A), previously shown to 157 have a dominant-negative effect 25 also yielded similar alterations ( Figure 2E ). 158
Consistent with a global deregulation of splicing in the absence of ATXN3, 159 microarray analysis ( Figure 2F ) using specific arrays containing additional 160 probes for exon/exon junctions, confirmed that 1993 genes (43%), from the 161 7450 differentially expressed probes in ATXN3 shRNA cells, presented 162 differentially regulated alternative splicing events (Table EV1 ). These genes 163 mainly encode components with function in protein degradation systems, cell 164 adhesion, axon guidance and various signaling pathways (Table EV2) , the 165 majority of splicing events being decreased when compared to control cells 166 (Table EV3 ). The most affected alternative splicing event types were exon 167 cassette usage (34%), complex splicing (20%) and intron retention (15%) 168 ( Figure 2G ). Alternative terminal exon usage, which can be mechanistically 169 linked to alternative splicing, was also seen in 16% of the cases ( Figure 2G ). 170
Being a key mechanism in the regulation of gene expression, defects in these 171 regulatory processes may affect a multiplicity of cellular functions related to 172 disease. 173
174

ATXN3 modulates SRSF7 degradation by the proteasome 175
Interestingly, among the splicing factors with differential ubiquitylation was the 176 Arginine/Serine-Rich splicing factor SRSF7 (also known as 9G8), known to be 177 involved in the regulation of alternative splicing of the neurodegeneration-178 related gene MAPT 33 , encoding the Tau protein. As shown in Figure 3A -B, 179
we detected decreased levels of ubiquitylated forms of SRSF7 in cells lacking 180 ATXN3 (p=0.02), validating the data obtained with the proteomic analysis. 181
Consistent with the hypothesis that the differential ubiquitylation of SRSF7 182
can have an impact on its degradation, the steady state levels of total (Figure 183 3A-B) and nuclear ( Figure 3C -D) SRSF7 were decreased in ATXN3 shRNA cells 184 as compared with the SCR shRNA control cells (p=0.025 and p=0.001, 185 respectively). This suggests that SRSF7 is indeed being more degraded in the 186 absence of ATXN3, confirming that ATXN3 affects the expression of SRSF7 187 at the protein and not at the mRNA level (p=0.712) ( Figure EV1C ). 188
Based on the fact that SRSF7 was captured using Agarose-TUBEs that have 189 higher affinity for polyubiquitylated than for monoubiquitylated proteins 30 and 190 considering that ATXN3 is a DUB, we asked if ATXN3 could modify 191 ubiquitylation and regulate degradation of SRSF7 through the UPP. 192
Supporting this possibility, the levels of SRSF7 were significantly increased in 193 ATXN3 shRNA cells upon proteasome inhibition with MG132 p=0.0016) (Figure 194 3E-F). Additionally, we detected lower levels of polyubiquitylated SRSF7 195 presenting Ub-K48 linkages ( Figure 3G ), a type of Ub chain that usually 196 signals proteins for degradation through the UPP. Protein stability analysis 197 upon inhibition of protein synthesis by cicloheximide treatment showed a 198 decrease in the half-life of SRSF7 in ATXN3 shRNA cells ( Figure 3H ), suggesting 199 that ATXN3 normally acts to inhibit SRSF7 degradation in neurons. In order 200 for ATXN3 to modify the ubiquitylation and stability of SRSF7, the two proteins 201 need to interact. Co-immunoprecipitation using protein extracts from 202 differentiated neuron-like SH-SY5Y cells confirmed that an interaction 203 between ATXN3 and SRSF7 occurs in these cells ( Figure 3I ). This interaction 204 was further confirmed in live cells by the Protein Ligation Assay ( Figure 3J , 205 Given that one of the splicing factors showing differential ubiquitylation was 210 SRSF7, we next analyzed mRNA levels of Tau isoforms in ATXN3 shRNA cells 211 to assess the functional impact of the reduction of this splicing factor in Tau 212 splicing. We found a significant decrease in the transcript levels of 4R-Tau 213 isoform (p=7.4x10 -11 ) ( Figure 4A ), but no alteration of the 3R-Tau isoform 214 (p=0.270) in ATXN3 shRNA cells as compared with SCR shRNA control cells 215 ( Figure 4B ), leading to an altered 4R/3R-Tau ratio (p=2,98x10 -6 ) and 216 decreased total tau levels (p=1.92x10 -4 ), both in ATXN3 shRNA cells ( Figure 4D ) 217 as well as in cultured primary cerebellar neurons (p=3.23x10 -9 ) in which 218 ATXN3 expression was silenced by shRNA ( Figure EV1D , Figure 4E -H). 219
Consistently, catalytically inactive (Dominant negative) ATXN3 expression 220 also led to alterations in tau expression and in the isoform ratio similar to 221 those seen in cells with silenced ATXN3: decreased expression of 4R-Tau 222 (p=1.1x10 -5 ) ( Figure 4I ), no alterations on the 3R-Tau isoform ( Figure 4J ), and 223 consequentially a decreased 4R/3R-Tau ratio (p=0.0088) ( Figure 4K ) and 224 decreased levels of total Tau (p=1.20x10 -6 ) ( Figure 4L ). To explore the 225 functional consequences of this reduction in 4R-Tau levels, we performed a 226 morphometric analysis of these cells. ATXN3 shRNA cultures presented a 227 decreased expression of βIII-tubulin and a decreased average length of the 228 neuritis as compared with the SCR shRNA controls, which correlates with a more 229 immature stage of neuronal differentiation ( Figure 4M-N) . 230
Decreased SRSF7 expression and Tau splicing perturbation in SCA3 232 models and patients 233
To determine if the presence of an expanded polyglutamine (polyQ) tract 234 within ATXN3 would lead to an alteration in this newly identified physiological 235 function, we analyzed a SH-SY5Y cell line expressing a version of ATXN3 236 bearing 83 glutamines (ATXN3_83Q), and found a globally decreased 237 efficiency of splicing ( Figure 5A ). We next asked whether the presence of the 238 polyQ tract could also impact MAPT mRNA splicing regulation, altering the 239 4R/3R-Tau ratio. Interestingly, expression of ATXN3_83Q lead to similar 240 changes in the expression of tau isoforms as observed in cells lacking ATXN3 241 or expressing a catalytic mutant version of this protein: i) decreased 242 expression of 4R-Tau isoform (p=6.6x10 -5 ) ( Figure 5B ), ii) no alterations on 243 the 3R-Tau isoform ( Figure 5C ), iii) a decrease of the 4R/3R-Tau ratio 244 (p=2.4x10 -4 ) ( Figure 5D ), and (iv) a decrease in the levels of total Tau 245 (p=7.6x10 -6 ) ( Figure 5E ).. Of notice, the overexpression of the wild type 246 ATXN3 (ATXN3_28Q) also caused some (albeit less important) degree of 247 perturbation ( Figure 5 A-E), pointing to the importance of a tight regulation of 248 ATXN3 dosage in neurons. 249
Tau splicing was also analyzed in SCA3 mouse model (CMVMJD135) that 250
reproduces key features of the disease 34 . A decreased expression of the 4R-251
Tau isoform was seen in the brainstem (affected brain region) of CMVMJD135 252 mice (Tg) (p=7x10 -5 ) comparing with the Wild type (Wt) controls ( Figure 5F ), 253 with no alterations of the 3R-Tau isoform expression (p=0.84) ( Figure 5G) , 254 leading to an altered 4R/3R-Tau ratio (p=1.2x10 -3 ) ( Figure 5H ) and decreased 255 levels of total Tau (p=1.1x10 -8 ) ( Figure 5I ). In addition, SRSF7 protein levels 256 were also reduced in the brainstem (p=0.0093), spinal cord (p=0.0014) and to 257 a lesser extent in the cerebellum (p=0.1138) (disease-affected brain areas) of 258
Tg mice as compared with the Wt littermate controls ( Figure 5J -L, 259 respectively), but no alterations at the mRNA level were detected (Figure 260 EV1F). This indicates that the impact of ATXN3 on tau splicing through the 261 control of SRSF7 levels is also occurring in SCA3 and is corroborated by the 262 decreased levels of SRSF7 protein present in the brains of SCA3 patients as 263 compared with healthy controls ( Figure 5M ). To explore the functional 264 consequences of this reduction in 4R-Tau levels, an isoform of Tau 265 associated with mature neurons and synaptic function, we performed a 266 morphometric analysis of neurons in this brain region. A decreased mean 267 neurite length (p=0.0189) ( Figure 5N Indeed, since many of these diseases exhibit ubiquitylated protein 279 aggregates, loss of ubiquitin homeostasis may be an important contributor for 280 disease. Considering the importance of DUB enzymes in maintaining the 281 ubiquitylation balance, we focused on the characterization of the ubiquitome 282 of neuronal cells lacking ATXN3 25 . Using TUBEs, that enable the pulldown of 283 polyubiquitylated proteins without further genetic manipulation or inhibition of 284 the proteasome 30 in combination with LC-MS/MS, we were able to 285 consistently identify 615 proteins per condition, a yield comparable to those 286 described in other studies 35, 36 . Among the proteins identified, approximately 287 one third presented altered levels of polyubiquitylation in ATXN3 shRNA cells. 288
Curiously, the majority of these proteins presented decreased levels in the 289 polyubiquitin-enriched fraction signal, suggesting that normally ATXN3 might 290 be preventing their degradation, for instance by editing the substrate's 291 ubiquitin chains, as we observed before for ITGA5 24,25 . Therefore, when 292 ATXN3 is silenced, the polyubiquitin signal is not removed, which may result 293 in an increased degradation of the targeted proteins. The fact that a significant 294 proportion of the proteins with altered polyubiquitylation levels in ATXN3 shRNA 295 cells were splicing factors and proteins involved in RNA processing, is 296 suggestive of ATXN3 playing a role in the pre-mRNA splicing process in 297 neuronal cells. This process is particularly important in generating diversity 298 and specificity in the central nervous system, which requires a wide protein 299 repertoire to generate its highly specialized and adaptable neuronal circuits 37 . 300
Given the importance of RNA processing for neuronal function, it comes as no 301 surprise that altered RNA processing is a contributing factor to the 302 pathogenesis of multiple neurodegenerative diseases [38] [39] [40] [41] [42] . Disruption of 303 alternative slipicing (AS) regulation, resulting from mutations or abnormal 304 expression of RNA-binding proteins, can lead to an imbalance or an 305 inappropriate expression pattern of key protein isoforms, with profound 306 consequences on cellular and organismal physiology. Indeed, the relative 307 concentration of splicing factors and hnRNPs, which may be regulated by the 308 Ub pathway, has been shown to regulate AS 43 . For example, it was shown 309 that the abundance of several splicing factors is differentially affected by 310 proteasome inhibition, and abnormal levels of these regulatory proteins were 311 associated with a different AS pattern 44 . Another study showed that the 312 splicing factor SRSF5 is targeted to proteasomal degradation as the cells 313 undergo terminal differentiation 45 . Consistently, assessed general splicing 314 efficacy was decreased in cells depleted of ATXN3, as shown using artificial 315 reporter minigenes, further supporting the involvement of ATXN3 in the 316 regulation of the splicing process. Additionally, genome wide microarray 317 analysis of endogenous splicing events confirmed that absence of ATXN3 318 leads to a dramatic alteration in the splicing pattern of a large number of 319 genes in neuronal cells, including genes related to protein degradation, 320 adhesion, axon guidance and signaling pathways. This is consistent with our 321 previous findings showing that absence of ATXN3 leads to an impairment in 322 neuronal differentiation and adhesion 25 , and affects the degradation of 323 several target proteins 23-25 . Significantly, a portion of the predicted splicing 324 regulators of these genes with altered splicing in cells lacking ATXN3 were 325 found to have altered levels of polyubiquitylation in our proteomic analysis, the 326 majority of them being Serine/Arginine (SR) -rich phosphoproteins. Proteins 327 of the SR family are key players in the control of AS, regulating the selection 328 of alternative sites 46,47 . The fact that SRSF7 (9G8), one of those proteins and 329 a key regulator of MAPT (tau) exon 10 splicing 48,49 , was captured using the 330 Agarose-TUBEs, which have high affinity for polyubiquitin chains 30 , 331
suggested that this splicing factor is polyubiquitylated, and thus might be 332 degraded through the UPP. Indeed, while it has been described that the 333 mature human neurons express approximately equal levels of 4R and 3R-Tau 334 isoforms 50,51 , whose expression is developmentally controlled and finely-335 tuned, we found that loss of function of ATXN3 disrupts this balance in 336 neuronal cells leading to a decreased 4R/3R-Tau ratio, that coincides with 337 (and may be caused by) decreased levels of SRSF7. Very recent works have 338 shown imbalanced expression in 3R and 4R-Tau, namely a decreased 339 expression of the 4R isoform as here observed, in the brain of a mouse model 340 of Down syndrome, but also in human AD and PD patients 52-54 , strengthening 341 the idea that a faulty tau exon 10 splicing might be contributing for the 342 pathogenesis of several neurodegenerative diseases. In addition, the 343 decreased levels of the 4R-Tau isoform presented by ATXN3 shRNA cells, also 344 correlate with the immature phenotype of these cells, that we previously 345 described 25 . Indeed Conejero-Godberg and colleagues also assessed the 346 transcriptional profiles related to 3R and 4R-Tau splice variants, revealing that 347 a cluster of genes related to neuronal cell morphology and outgrowth of 348 neurites is upregulated in the presence of 4R isoforms, while genes related to 349 cellular growth and proliferation were downregulated 55 . This is in agreement 350 with previous work from Sennvik's team establishing a role for 4R-Tau 351 isoforms in promoting neuronal differentiation 56 . Taking into account that loss 352 of function of ATXN3 leads to a deregulation in the amount of SRSF7, at the 353 protein level but not RNA level, we hypothesized that this splicing factor could 354 be a substrate of the DUB activity of ATXN3, which could be modulating its 355 degradation. In line with that, we confirmed that ATXN3 interacts closely with 356 SRSF7 in neuronal cells, suggesting that these proteins are molecular 357 partners in such cells, and establishing a functional link between two key 358 proteins involved in different neurodegenerative diseases. Trying to explore if 359 this interaction could be indicative that ATXN3 is modulating the degradation 360 of SRSF7 through the proteasome, we measured the levels of this protein 361 upon proteasome inhibition; as expected, we saw an accumulation of SRSF7 362 when the proteasome was inhibited. Interestingly, we also found a decreased 363 4R/3R-Tau ratio, as well as decreased protein levels of SRSF7, both in cells 364 expressing the mutant protein, in affected brain regions of our mouse model 365 for the disease, at an age when the transgenic animals display an overt 366 phenotype resembling behavioral and pathological characteristics present in 367 human patients 34 . This suggests that the mis-splicing of tau may be 368 contributing to SCA3 pathogenesis, as it does to other neurodegenerative 369 diseases. Considering that we observed a similar phenomenon using cells 370 lacking ATXN3 and cells expressing a catalytic inactive mutant form of the 371 protein, it is reasonable to think that the DUB activity of ATXN3 is important in 372 this cellular process and that the polyglutamine expansion might cause a 373 partial loss of this normal function of the protein (even in presence of 50% of 374 the wild type protein), perhaps through a dominant negative mechanism, thus 375 contributing to SCA3 pathogenesis. Indeed, Winborn and co-workers 376 demonstrated that while expression of ataxin-3 with a non-pathogenic polyQ 377 tract leads to a reduction in total ubiquitylated protein levels in cells, this 378 reduction is not observed upon overexpression of an expanded ataxin-3, 379 which may reflect inefficient deubiquitylation of cellular proteins, pointing to an 380 overall loss of function 57 . Overall, our data suggest that ATXN3 is involved in 381 splicing regulation through the modulation of the ubiquitylation of splicing 382
factors. This regulatory role may be mediated through the DUB activity of 383 ATXN3 by modulating activation, degradation and/or subcellular localization of 384 the splicing factors, or may be an indirect result of the modulation of E3 385 ligases specific for these targets. 
Digestion of proteins from preparative 1D-PAGE gel 462
The 1D PAGE LC-MS/MS approach was used for protein identification as 463 previously described 65 . Eluted proteins were separated using 1.5 mm and 464 10% SDS-PAGE gels. The quality of purification was controlled by Coomassie 465
Brilliant Blue g-250 (Sigma) staining before MS analysis. Gel image was 466 acquired the Gel Doc™ EZ system (Bio-rad). After Coomassie staining, all the 467 visible blue-stained protein spots were manually excised from the gel. The gel 468 pieces were destained overnight at room temperature using 50% acetonitrile 469 in 25 mM ammonium bicarbonate buffer, pH 8.5, and then dehydrated with 470 100% acetonitrile. The shrunken pieces were then re-swollen in 50 mM 471 ammonium bicarbonate buffer, dehydrated in 100% acetronitrile and dried in a 472 speedvac® concentrator (Savant) for 30 min. The gel pieces were rehydrated 473 in 60 µL of 20 µg/mL Trypsin (Promega) in 50 mM ammonium bicarbonate 474 solution and incubated for 2h at 55ºC. The gel pieces were then incubated 475 with 0.1% trifluoroacetic acid in 50% acetonitrile for 20 min at room 476 temperature in order to extract the remaining peptides from the gel. The 477 tryptic peptides were dried in a speedvac for 2 h. 478
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 480
After re-dissolution in 17 µL 0.1% acetic acid, samples were separated on a 481 capillary C18 column using a nano LC-ultra 1D 
RNA extraction and Array hybridization 497
Total RNA was isolated from ATXN3 shRNA and SCR shRNA cells using an 498 miRNeasy mini kit (Qiagen) and quality assessment was achieved using RNA 499 6000 Nano labchip (Bioanalyzer, Agilent) and by a Nanodrop 500 spectrophotometer (Thermo). Total RNAs RIN values were between 8.7 and well plates previously coated with Matrigel (BD, Biosciences), and 10 μM all-602 trans-retinoic acid (Sigma Aldrich) was added the day after plating in DMEM-603 F12 with 1% FBS, to induce differentiation. After 5 days, cells were washed in 604 DMEM/F-12 and incubated with 50 ng/mL BDNF (Prepotech) in DMEM/F-12 605 without serum for 3 days. Cells were then labeled for β-III tubulin (1:1000, 606 R&D Systems), scanned at different locations of each well and the 607 quantitative analysis of neurite length were automatically done using the 608 automatic imaging system Thermo Scientific Cellomics® ArrayScan® VTI. 609 610 Immunoprecipitation 611
RA-treated cells were washed in ice-cold PBS and lysed by sonication on ice 612
in NP-40 buffer. Aliquots were taken from protein extracts as 10% inputs. 1 613 mg of total protein was pre-cleared for 3 h at 4ºC by incubation with 614 glutathione-coupled sepharose beads (GE Healthcare) previously equilibrated 615 in Wash buffer 1 (50 mM Tris-HCl pH 7.5, 150 nM NaCl, 1% NP-40, 1x 616 protease inhibitors (Roche)) for 3 times, 10 min at 4ºC. Beads were then 617 centrifuged and the supernatant was incubated O/N at 4ºC with 50 μL 618 equilibrated beads. After centrifugation, the supernatant was discarded and 619 the beads were washed 2 times with Wash buffer 1 for 10 min at 4ºC. Beads 620 were then washed twice with Wash buffer 2 (50 mM Tris-HCl pH 7.5, 500 mM 621 NaCl, 0.1% NP-40) for 10 min at 4ºC, and once with Wash buffer 3 (50 mM 622
Tris-HCL pH 7.5, 0.1% NP-40) for 20 min at 4ºC. The supernatant was 623 discarded and the bound proteins were eluted with 1x Laemmli buffer, boiled 624
for 5 min at 98ºC and run in a 10% SDS-PAGE gel. 625 626 Proximity Ligation Assay (PLA) 627 SH-SY5Y cells were cultured onto polyD-lysine coated cover slips in 24-well 628 plates using D-MEM media as indicated to above. PLA protocol was 629 performed as described in 67 and following manufacturer instructions with 630 adaptations. Cells were fixed with 4% PFA, and permeabilized with 0.5% 631
Triton in PBS at room temperature. Blocking was performed at 37ºC in a 632 humidity chamber for 1 hour, using Duolink® PLA Blocking Solution (Sigma). 633
Primary antibodies were incubated over night at 4ºC followed by two washing 634 steps of 5 minutes with Wash Buffer A (Sigma) at room temperature. PLUS 635 and MINUS PLA probes were diluted 1:5 in the Duolink Antibody Diluent 636 (Sigma), added to the cover slips and incubated for 1h at 37ºC in a humidity 637 chamber. Washing was performed for 5 minutes two times with Washing 638
Buffer A at room temperature followed by incubation with Ligase solution 639 (Sigma) for 30 minutes at 37ºC in a humidity chamber. After washing two 640 times during 2 minutes with Washing Buffer A at room temperature, cover 641 slips were incubated with Amplification solution (Sigma) for 100 minutes at 642 37ºC in a humidity chamber protected from light. Then, cover slips were 643 washed two times during 10 minutes with Washing Buffer B (Sigma) at room 644 temperature followed by an additional washing step of 1 minute using 100X 645 
